{"related:55bfm2g-FN8J:scholar.google.com/&scioq=systemic+therapy&hl=en&as_sdt=0,5":[{"title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","url":"https://www.sciencedirect.com/science/article/pii/S1470204516301073","authors":["TK Choueiri","TK Choueiri B Escudier","TK Choueiri B Escudier T Powles","TK Choueiri B Escudier T Powles NM Tannir…"],"year":2016,"numCitations":565,"pdf":"https://helda.helsinki.fi/bitstream/handle/10138/224076/Cabozantinib_versus_everolimus.pdf?sequence=1&isAllowed=y","citationUrl":"http://scholar.google.com/scholar?cites=16074541589004785383&as_sdt=2005&sciodt=0,5&hl=en&scioq=systemic+therapy","relatedUrl":"http://scholar.google.com/scholar?q=related:55bfm2g-FN8J:scholar.google.com/&scioq=systemic+therapy&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=16074541589004785383&hl=en&as_sdt=0,5&scioq=systemic+therapy","publication":"Elsevier","p":1,"exp":1596876833731},{"title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/nejmoa1510016","authors":["TK Choueiri","TK Choueiri B Escudier","TK Choueiri B Escudier T Powles…"],"year":2015,"numCitations":765,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa1510016","citationUrl":"http://scholar.google.com/scholar?cites=15416788208830885159&as_sdt=2005&sciodt=0,5&hl=en&scioq=systemic+therapy","relatedUrl":"http://scholar.google.com/scholar?q=related:J63LvDFv89UJ:scholar.google.com/&scioq=systemic+therapy&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=15416788208830885159&hl=en&as_sdt=0,5&scioq=systemic+therapy","publication":"Mass Medical Soc"},{"title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","url":"https://www.sciencedirect.com/science/article/pii/S1470204515002909","authors":["RJ Motzer","RJ Motzer TE Hutson","RJ Motzer TE Hutson H Glen","RJ Motzer TE Hutson H Glen MD Michaelson…"],"year":2015,"numCitations":540,"pdf":"http://www.academia.edu/download/62011744/The_Lancet_Oncology_Lenvatinib_mRCC_10_15_201520200206-12162-s53hwh.pdf","citationUrl":"http://scholar.google.com/scholar?cites=4253233843226512535&as_sdt=2005&sciodt=0,5&hl=en&scioq=systemic+therapy","relatedUrl":"http://scholar.google.com/scholar?q=related:l4wvVKWFBjsJ:scholar.google.com/&scioq=systemic+therapy&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=4253233843226512535&hl=en&as_sdt=0,5&scioq=systemic+therapy","publication":"Elsevier"},{"title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 …","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5455807/","authors":["TK Choueiri","TK Choueiri S Halabi","TK Choueiri S Halabi BL Sanford","TK Choueiri S Halabi BL Sanford O Hahn…"],"year":2017,"numCitations":386,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5455807/","citationUrl":"http://scholar.google.com/scholar?cites=5181895643400921433&as_sdt=2005&sciodt=0,5&hl=en&scioq=systemic+therapy","relatedUrl":"http://scholar.google.com/scholar?q=related:WWEOAKLK6UcJ:scholar.google.com/&scioq=systemic+therapy&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=5181895643400921433&hl=en&as_sdt=0,5&scioq=systemic+therapy","publication":"ncbi.nlm.nih.gov"},{"title":"Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma","url":"https://www.nature.com/articles/onc2015343","authors":["L Zhou","L Zhou XD Liu","L Zhou XD Liu M Sun","L Zhou XD Liu M Sun X Zhang","L Zhou XD Liu M Sun X Zhang P German","L Zhou XD Liu M Sun X Zhang P German S Bai…"],"year":2016,"numCitations":207,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791213/","citationUrl":"http://scholar.google.com/scholar?cites=8808556425904609992&as_sdt=2005&sciodt=0,5&hl=en&scioq=systemic+therapy","relatedUrl":"http://scholar.google.com/scholar?q=related:yFoHTmZHPnoJ:scholar.google.com/&scioq=systemic+therapy&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=8808556425904609992&hl=en&as_sdt=0,5&scioq=systemic+therapy","publication":"nature.com"},{"title":"Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial","url":"https://www.sciencedirect.com/science/article/pii/S1470204513700937","authors":["RJ Motzer","RJ Motzer B Escudier","RJ Motzer B Escudier P Tomczak","RJ Motzer B Escudier P Tomczak TE Hutson…"],"year":2013,"numCitations":629,"citationUrl":"http://scholar.google.com/scholar?cites=6535083068699311642&as_sdt=2005&sciodt=0,5&hl=en&scioq=systemic+therapy","relatedUrl":"http://scholar.google.com/scholar?q=related:Gv59N21HsVoJ:scholar.google.com/&scioq=systemic+therapy&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=6535083068699311642&hl=en&as_sdt=0,5&scioq=systemic+therapy","publication":"Elsevier"},{"title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1303989","authors":["RJ Motzer","RJ Motzer TE Hutson","RJ Motzer TE Hutson D Cella","RJ Motzer TE Hutson D Cella J Reeves…"],"year":2013,"numCitations":1434,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa1303989","citationUrl":"http://scholar.google.com/scholar?cites=5593415504868596567&as_sdt=2005&sciodt=0,5&hl=en&scioq=systemic+therapy","relatedUrl":"http://scholar.google.com/scholar?q=related:V9vaOMTNn00J:scholar.google.com/&scioq=systemic+therapy&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=5593415504868596567&hl=en&as_sdt=0,5&scioq=systemic+therapy","publication":"Mass Medical Soc"},{"title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","url":"https://www.sciencedirect.com/science/article/pii/S0140673611616139","authors":["BI Rini","BI Rini B Escudier","BI Rini B Escudier P Tomczak","BI Rini B Escudier P Tomczak A Kaprin","BI Rini B Escudier P Tomczak A Kaprin C Szczylik…"],"year":2011,"numCitations":1695,"citationUrl":"http://scholar.google.com/scholar?cites=3547505814206124423&as_sdt=2005&sciodt=0,5&hl=en&scioq=systemic+therapy","relatedUrl":"http://scholar.google.com/scholar?q=related:h5FjFr5FOzEJ:scholar.google.com/&scioq=systemic+therapy&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=3547505814206124423&hl=en&as_sdt=0,5&scioq=systemic+therapy","publication":"Elsevier"},{"title":"Cabozantinib for the treatment of renal cell carcinoma","url":"https://www.tandfonline.com/doi/abs/10.1080/14656566.2016.1258059","authors":["B Escudier","B Escudier JC Lougheed","B Escudier JC Lougheed L Albiges"],"year":2016,"numCitations":7,"pdf":"https://www.tandfonline.com/doi/pdf/10.1080/14656566.2016.1258059","citationUrl":"http://scholar.google.com/scholar?cites=14999505601858295116&as_sdt=2005&sciodt=0,5&hl=en&scioq=systemic+therapy","relatedUrl":"http://scholar.google.com/scholar?q=related:TNU-xd_yKNAJ:scholar.google.com/&scioq=systemic+therapy&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=14999505601858295116&hl=en&as_sdt=0,5&scioq=systemic+therapy","publication":"Taylor & Francis"}]}